- Home
- BCDA vs LDTC Comparison
BCDA vs LDTC Comparison
Compare BCDA & LDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- LDTC
- Stock Information
- Founded
- BCDA N/A
- LDTC 2007
- Country
- BCDA United States
- LDTC Canada
- Employees
- BCDA N/A
- LDTC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- LDTC Blank Checks
- Sector
- BCDA Health Care
- LDTC Finance
- Exchange
- BCDA Nasdaq
- LDTC Nasdaq
- Market Cap
- BCDA 7.9M
- LDTC 9.4M
- IPO Year
- BCDA N/A
- LDTC N/A
- Fundamental
- Price
- BCDA $1.85
- LDTC $0.32
- Analyst Decision
- BCDA Strong Buy
- LDTC Buy
- Analyst Count
- BCDA 1
- LDTC 3
- Target Price
- BCDA $25.00
- LDTC $1.00
- AVG Volume (30 Days)
- BCDA 61.9K
- LDTC 157.8K
- Earning Date
- BCDA 11-13-2024
- LDTC 08-14-2024
- Dividend Yield
- BCDA N/A
- LDTC N/A
- EPS Growth
- BCDA N/A
- LDTC N/A
- EPS
- BCDA N/A
- LDTC N/A
- Revenue
- BCDA $71,000.00
- LDTC $6,052,694.00
- Revenue This Year
- BCDA $6.92
- LDTC N/A
- Revenue Next Year
- BCDA N/A
- LDTC $2.28
- P/E Ratio
- BCDA N/A
- LDTC N/A
- Revenue Growth
- BCDA N/A
- LDTC 2.76
- 52 Week Low
- BCDA $1.84
- LDTC $0.22
- 52 Week High
- BCDA $12.00
- LDTC $11.20
- Technical
- Relative Strength Index (RSI)
- BCDA 29.98
- LDTC 59.16
- Support Level
- BCDA $2.21
- LDTC $0.28
- Resistance Level
- BCDA $2.47
- LDTC $0.35
- Average True Range (ATR)
- BCDA 0.16
- LDTC 0.04
- MACD
- BCDA -0.04
- LDTC 0.01
- Stochastic Oscillator
- BCDA 1.30
- LDTC 75.97
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.